


Management of Patients with IBD during the COVID-19 Pandemic

Source: Rubin DT, Feuerstein JD, Wang AY, Cohen RD, AGA Clinical Practice Update on Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: Expert Commentary, Gastroenterology (2020)



* Symptoms and findings of COVID-19: fever (83-99%); cough (59-82%); fatigue (44-70%); anorexia (40-84%); shortness of breath (31-40%); sputum production (28-33%); myalgias (11-35%); headache, confusion, rhinorrhea, sore throat, hemoptysis, vomiting, and diarrhea (<10%); lymphopenia (83%); CT chest: bilateral, peripheral ground glass opacities. Reference: CDC - Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19). <https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html>. Accessed April 2, 2020.

** Clearance of SARS-Cov-2 may enable resumption of IBD therapy; role of serologic antibody testing unclear at the current time. (Viral clearance testing may or may not be possible or appropriate, given local testing capabilities and health system-approved epidemiological testing strategies during the COVID-19 pandemic.)

*** Treatment of COVID-19 under investigation, consider therapies that have safety and efficacy in IBD.